Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 832-827-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 16 July 2019 to 01 August 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 019
- Report date:
- 2019
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- OECD Guidelines for the Testing of Chemicals (No.: 402, 09 October 2017)
- Deviations:
- yes
- Remarks:
- See "Any other information" for details
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Version / remarks:
- Commission Regulation (EC) No 440/2008, B.3 (L 142, 30 May 2008)
Note: This guideline has not yet been revised in line with the OECD 2017 version. The study does not fully comply with the older version of the guideline, but the study design is considered to be acceptable for all OECD countries. - Deviations:
- yes
- Remarks:
- See "Any other information" for details
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Version / remarks:
- OPPTS 870.1200 (EPA 712-C-98-192, August 1998)
Note: The guideline has not yet been revised in line with the OECD 2017 version. The study does not fully comply with the older version of the guideline, but the study design is considered to be acceptable for all OECD countries. - Deviations:
- yes
- Remarks:
- See "Any other information" for details
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- Oligomerisation products of alpha-alkenes C16-18 (even numbered), hydrogenated, hydroisomerised
- EC Number:
- 832-827-5
- Cas Number:
- 2241366-04-9
- Molecular formula:
- Variable - UVCB
- IUPAC Name:
- Oligomerisation products of alpha-alkenes C16-18 (even numbered), hydrogenated, hydroisomerised
- Test material form:
- liquid
- Details on test material:
- Name: SynNova Base Oil
CAS number: 2241366-04-9
Batch/Lot number: TS20371/TS21270
Description: Liquid - water white colorless oil.
Purity: 100%
Expiry date: 25 February 2021/31 July 2021
Storage conditions: Controlled room temperature (15-25°C, ≤70% relative humidity)
Safety precautions: Routine safety precautions (gloves, goggles, face mask, lab coat) for unknown materials were applied to ensure personnel health and safety.
Constituent 1
- Specific details on test material used for the study:
- No further details specified in the study report.
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Species and strain: Crl: WI Wistar rats
Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld, Germany
Hygienic level at arrival: SPF
Hygienic level during the study: Standard housing conditions
Justification of strain: The Wistar rat is one of the standard rodent species used in acute toxicity studies.
Number of animals: 3 animals
Sex: Female, nulliparous and non-pregnant.
Age of animals at study start: 11 weeks old
Body weight range at dosing: Between 264 g and 288 g
Acclimation time: 28 or 30 days
Animal health: Only healthy animals were used for the study. The staff Veterinarian certified the health status.
Housing / Enrichment: Individual caging during the treatment, group caging after patch removal. Rodents were housed with deep wood sawdust bedding to allow digging and other normal rodent activities. Mini Fun Tunnel (produced by LBS (Serving Biotechnology) Ltd., United Kingdom) was also available for the animals during the study.
Cage type: Type II. polypropylene/polycarbonate
Bedding: SAFE 3/4-S Hygienic Animal Bedding (produced by J. Rettenmaier & Söhne GmbH+CO.KG, Germany) was available to animals during the study. The quality of the bedding was guaranteed by the supplier. Details of bedding quality are archived with the raw data.
Nesting: Nest building material Arbocel Crinklets natural (produced by J. Rettenmaier & Söhne GmbH+CO.KG, Germany) was available to animals during the study. The quality of the nest building material was guaranteed by the supplier. Details of nest building material quality are archived with the raw data.
Light: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Temperature: 20.2–26.0°C
Relative humidity: 32–74%
Ventilation: 15-20 air exchanges/hour
Temperature and relative humidity were recorded twice daily during the study.
Food and Water Supply: Animals received ssniff® SM R/M "Autoclavable complete diet for rats and mice – breeding and maintenance" produced by ssniff Spezialdiäten GmbH, D-59494 Soest, Germany (Batch number: 639 38520, expiry date: 30 April 2019) ad libitum, and tap water from the municipal supply, as for human consumption from a 500 mL bottle, ad libitum. The food is considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study and the water was considered fit for human consumption.
The supplier provided an analytical certificate for the batch used.
Water quality control analysis is performed once every three months and microbiological assessment is performed monthly by Veszprém County Institute of State Public Health and Medical Officer Service.
Animal Identification: Animals were individually identified using numbers written on the tail with an indelible pen. The numbers were given on the basis of Citoxlab Hungary Ltd.'s Master File for each animal allocated to the treatment groups. The cages were identified by cards containing information about study code, sex, dose group, cage number and individual animal number.
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- The test item was administered as supplied (no formulation of the test item was done).
The back of each animal was shaved (approximately 10% area of the total body surface) approximately 24 hours prior to treatment. The test item was applied to the shaved skin as a single dose and remained in contact with the skin for the 24-hour exposure period. Sterile gauze pads were placed on the skin of rats to cover the test item. These gauze pads were kept in contact with the skin using a patch with adhesive hypoallergenic plaster. The entire trunk of the animal was then wrapped with semi occlusive plastic wrap for 24 hours.
At the end of the exposure period, the treated area of skin with the test item was washed with water at body temperature. - Duration of exposure:
- 24 hours
- Doses:
- A single dermal application at 2000 mg/kg bw
- No. of animals per sex per dose:
- Dose range finding test: 1 female
Min study: 2 females - Control animals:
- not specified
- Details on study design:
- Mortality and Clinical Observations: Mortality/morbidity was checked twice daily during the 14-day observation period. Clinical observations were performed on the day of treatment at approximately 30 minutes, 1, 2 and 5 hours after application of the test item and once each day for 14 days thereafter. Observations included the skin and fur, eyes and mucous membranes, the respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Skin Irritation: Adverse skin reactions at the site of application were recorded daily following the removal of the dressing.
Measurement of Body Weight: The body weights were recorded on Day 0 (before the test item administration) and on Days 7 and 14 (before necropsy).
Necropsy: Macroscopic examination was performed on all animals. All animals were anaesthetised with sodium pentobarbital and exsanguinated. Following confirmation of death, after examination of the external appearance, the cranial, thoracic and abdominal cavities were opened and the appearance of the tissues and organs was observed. All macroscopic changes were recorded. - Statistics:
- Not specified
Results and discussion
- Preliminary study:
- Initially one animal was dosed at the selected limit dose (2000 mg/kg bw). As the animal survived, the second and third animal received the same dose.
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- The test item did not cause mortality at the dose level of 2000 mg/kg bw.
- Clinical signs:
- other: other: There were no adverse clinical signs noted in any animals during the 14-day observation period. No adverse local dermal signs (erythema/oedema) were noted in any animals during the 14-day observation period.
- Gross pathology:
- There was no evidence of any gross macroscopic changes at a dose level of 2000 mg/kg bw.
Any other information on results incl. tables
Clinical Observations and Local Dermal Signs
DOSE LEVEL: 2000 mg/kg bw, Treatment in Day 0 SEX: FEMALE
Cage No. |
Animal Number |
Observations |
Observation days |
Frequency |
|||||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||||||
30’ |
1h |
2h |
5h |
||||||||||||||||||
1 |
8388 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
18/18 |
2 |
8391 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
18/18 |
3 |
8392 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
18/18 |
Local Dermal Signs
DOSE LEVEL: 2000 mg/kg bw, Treatment in Day 0 SEX: FEMALE
Cage No. |
Animal Number |
Observations |
Observation days |
Frequency |
|||||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||||||
30’ |
1h |
2h |
5h |
||||||||||||||||||
1 |
8388 |
Erythema & Eschar-Draize |
- |
- |
- |
- |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14/18 |
|
|
Oedema-Draize |
- |
- |
- |
- |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14/18 |
2 |
8391 |
Erythema & Eschar-Draize |
- |
- |
- |
- |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14/18 |
|
|
Oedema-Draize |
- |
- |
- |
- |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14/18 |
3 |
8392 |
Erythema & Eschar-Draize |
- |
- |
- |
- |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14/18 |
|
|
Oedema-Draize |
- |
- |
- |
- |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14/18 |
Remarks: + = present - = absent
h = hour (s) ‘ = minute
Frequency of observations = number of occurrence of observation / total number of observations
Erythema severities: 0 = No erythema; 1 = very slight; 2 = Well-defined; 3 = Moderate to severe; 4 = Severe + slight eschar formation
Oedema severities: 0 = No oedema; 1 = Very slight; 2 = Slight; 3 = Moderate; 4 = Severe
Body Weight Data
DOSE LEVEL: 2000 mg/kg bw, Treatment on day 0 SEX: FEMALE
Cage No. |
Animal Number |
Body weight (g) |
Body Weight Gain (g) |
||||
0 |
7 |
14 |
0-7 |
7-14 |
0-14 |
||
1 |
8388 |
288 |
294 |
313 |
6 |
19 |
25 |
2 |
8391 |
268 |
269 |
276 |
1 |
7 |
8 |
3 |
8392 |
264 |
266 |
267 |
2 |
1 |
3 |
Mean: |
273.3 |
276.3 |
285.3 |
3.0 |
9.0 |
12.0 |
|
Standard deviation: |
12.9 |
15.4 |
24.4 |
2.6 |
9.2 |
11.5 |
Macroscopic Findings
DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 SEX: FEMALE
Cage No. |
Animal Number |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ/Tissue |
1 |
8388 |
30 July 2019 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
2 |
8391 |
01 August 2019 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
3 |
8392 |
01 August 2019 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test item SynNova Base Oil was found to be greater than 2000 mg/kg body weight in female Crl: WI rats.
According to the GHS criteria, SynNova Base Oil can be ranked as "Category 5 or Unclassified" for acute dermal exposure. - Executive summary:
An acute dermal toxicity study was performed with the test item SynNova Base Oil in female Crl: WI Wistar rats, in compliance with OECD Guideline No.: 402 (2017), Commission Regulation (EC) No 440/2008, B.3 and OPPTS 870.1200.
This study was being performed with vertebrate animals as no in vitro alternative is available. The Sponsor confirmed previously that the specific regulatory purpose of this study did not allow a waiving of this dermal acute study, taking account of the OECD guidance document 237.
A single animal at a dose level of 2000 mg/kg body weight (bw) was used in a range-finding phase, followed by two animals in the main phase to confirm the expected non-lethal dose level. The test item was applied as a single dermal 24-hour exposure followed by a 14-day observation period.
Clinical observations were performed on all animals at approximately 30 minutes, 1, 2, 5 hours after dosing and daily for 14 days thereafter. Body weight was measured on Day 0 (prior to dosing) and on Days 7 and 14 (before necropsy). Gross macroscopic examination was performed on all animals at necropsy at the end of the 2-week observation period (Day 14).
The results of the study were summarised as follows:
Mortality
Test item did not cause mortality at the dose level of 2000 mg/kg bw.
Clinical observations and local dermal signs
There were no adverse clinical signs noted in any animals during the 14-day observation period.
No adverse local dermal signs (erythema/oedema) were noted in any animals during the 14-day observation period.
Body weight and body weight gain
The body weights of the animals were within the range commonly recorded for this strain and age.
Necropsy
There was no evidence of any macroscopic changes at a dose level of 2000 mg/kg bw.
Conclusions
The acute dermal median lethal dose (LD50) of the test item SynNova Base Oil was found to be greater than 2000 mg/kg body weight in female Crl: WI rats.
According to the GHS criteria, SynNova Base Oil can be ranked as "Category 5 or Unclassified" for acute dermal exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.